OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING INFLAMMATORY LUNG DISEASES
Aspects of the disclosure relate to methods of using oligosaccharide compositions as microbiome metabolic therapies for treating inflammatory lung diseases and disorders, such as chronic obstructive pulmonary disease (COPD) and asthma.
1 . A method of treating and/or preventing an inflammatory lung disease or disorder in a subject, the method comprising administering to the gastrointestinal tract of the subject an effective amount of an oligosaccharide composition, wherein the oligosaccharide composition has an average degree of polymerization of 5-20 and comprises a plurality of oligosaccharides selected from Formula (I), Formula (II), and Formula (III):
wherein each R independently is selected from hydrogen, and Formulae (Ia), (Ib), (Ic), (Id), (IIa), (IIb), (IIc), (IId), (IIa), (IIIb), (IIIc), (IIId):
wherein each R independently is as defined above;
thereby treating and/or preventing the inflammatory lung disease or disorder.
2 . A method comprising:
(A) identifying a subject having an inflammatory lung disease or disorder; and
(B) treating the subject with an oligosaccharide composition having an average degree of polymerization of 5-20 and comprises a plurality of oligosaccharides selected from Formula (I), Formula (II), and Formula (III):
wherein each R independently is selected from hydrogen, and Formulae (Ia), (Ib), (Ic), (Id), (IIa), (IIb), (IIc), (IId), (IIIa), (IIIb), (IIIc), (IIId):
wherein each R independently is as defined above.
3 . A method of treating and/or preventing having an inflammatory lung disease or disorder in a subject, the method comprising administering to the gastrointestinal tract of the subject an effective amount of an oligosaccharide composition, wherein the oligosaccharide composition is produced from a mixture comprising glucose, galactose, and mannose,
thereby treating and/or preventing inflammatory lung disease or disorder.
4 . (canceled)
5 . (canceled)
6 . The method of any one of claims 1-3 , wherein the subject has dysbiosis of the lung microbiome
7 . (canceled)
8 . (canceled)
9 . (canceled)
10 . (canceled)
11 . (canceled)
12 . (canceled)
13 . (canceled)
14 . (canceled)
15 . (canceled)
16 . (canceled)
17 . (canceled)
18 . (canceled)
19 . (canceled)
20 . (canceled)
21 . (canceled)
22 . (canceled)
23 . (canceled)
24 . (canceled)
25 . (canceled)
26 . The method of claim 1 , wherein the subject has increased relative or absolute abundance of pathogenic bacteria in their lungs relative to a healthy subject.
27 . The method of claim 26 , wherein administration of the oligosaccharide composition reduces the relative or absolute abundance of pathogenic bacteria in the lungs, sputum and/or gut of the subject relative to a control subject or a baseline measurement.
28 . The method of claim 26 , wherein the subject has increased levels of Moraxella catarrhalis, Haemophilus influenzae and/or Streptococcus pneumoniae in their lungs relative to a healthy subject.
29 . (canceled)
30 . The method of any one of claims 1-3 , wherein the oligosaccharide composition promotes increased relative or absolute abundance of commensal bacteria in the lungs, sputum and/or gut of the subject.
31 . The method of claim 30 , wherein the oligosaccharide composition promotes increased relative or absolute abundance of one or more of Lactobacillus, Parabacteroides and Bacteroides.
32 . The method of any one of claims 1-3 , wherein the subject is more susceptible to respiratory viral infections than a healthy subject.
33 . (canceled)
34 . (canceled)
35 . (canceled)
36 . (canceled)
37 . (canceled)
38 . (canceled)
39 . (canceled)
40 . (canceled)
41 . (canceled)
42 . (canceled)
43 . (canceled)
44 . (canceled)
45 . (canceled)
46 . (canceled)
47 . (canceled)
48 . (canceled)
49 . (canceled)
50 . (canceled)
51 . (canceled)
52 . (canceled)
53 . (canceled)
54 . (canceled)
55 . (canceled)
56 . (canceled)
57 . (canceled)
58 . (canceled)
59 . (canceled)
60 . (canceled)
61 . (canceled)
62 . (canceled)
63 . (canceled)
64 . (canceled)
65 . (canceled)
66 . (canceled)
67 . (canceled)
68 . (canceled)
69 . (canceled)
70 . (canceled)
71 . (canceled)
72 . (canceled)
73 . (canceled)
74 . (canceled)
75 . (canceled)
76 . (canceled)
77 . The method of any one of claims 1-3 , wherein the method prevents the inflammatory lung disease or disorder.
78 . The method of claim 77 , wherein the inflammatory lung disease or disorder is a viral respiratory infection.